Retatrutide is a newer experimental peptide being researched for obesity, diabetes, appetite reduction, and fat loss, working similarly to GLP-1 medications by targeting GLP-1, GIP, and glucagon receptors simultaneously, with studies showing significant weight-loss effects, reduced appetite, and improved blood sugar control.